Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes

Abstract

Aim: To compare the potential amelioration of dyslipidemia and LDL particle size by alogliptin and voglibose in patients with impaired glucose tolerance (IGT) or Type 2 diabetes mellitus (T2DM). Patients & methods: Patients (n = 37; 25 patients with IGT and 12 patients with newly diagnosed T2DM) were randomly assigned to treatment with either alogliptin (25 mg daily for 12 weeks) or voglibose (0.6 mg daily for 12 weeks). A 75-g oral glucose tolerance test and laboratory measurements were performed at baseline and after treatment. LDL particle size was evaluated by electrophoresis of lipoproteins. Results: Following treatment, alogliptin, but not voglibose, decreased triglycerides (p < 0.01) and increased HDL cholesterol (p < 0.05), and significantly decreased the relative mobility value (p < 0.05). Conclusion: Alogliptin ameliorates dyslipidemia and increases LDL particle size in patients with IGT or T2DM.

Keywords::

• alogliptin
• DPP-4 inhibitor
• dyslipidemia
• impaired glucose tolerance
• LDL particle size
• Type 2 diabetes
• voglibose